Compared with LHRH agonists, anti-androgen drugs show poor survival results, so LHRH agonists have a more comprehensive range of applications in the treatment of prostate cancer (Seidenfeld et al., 2000). This evidence concerns the gene GNRH1 and prostate carcinoma.